South America Pharmaceutical Cold Chain Logistics Market: Market Size & Forecast 2026

The South America pharmaceutical cold chain logistics market covers end-to-end temperature-controlled services from API manufacturers through to hospitals, pharmacies, and clinical trial sites. Brazil anchors regional demand because of its large population, domestic vaccine and biologics manufacturing base, and role as a distribution hub for neighboring countries. Argentina, Chile, and Colombia are smaller but rapidly developing markets, supported by growing biologics imports and expanding clinical research activity.

• •Market size approximately USD 0.55 billion in 2025 with a compound annual growth rate of about 9.6%.
• •Brazil accounts for the largest share of regional pharmaceutical cold chain spend, followed by Argentina, Mexico (trade-linked), Colombia, and Chile.
• •Demand is concentrated around vaccines, insulin, oncology biologics, and advanced therapies that require strict 2-8°C or ultra-cold handling.

Three forces are pulling the market forward: rising volumes of high-value biologics, broader vaccine coverage programs, and regulatory pressure for demonstrable temperature control. Public immunization initiatives, including expanded pediatric and adult schedules, are creating more cold-chain touchpoints, while private-sector growth in chronic disease treatments is increasing demand for insulin and specialty drug distribution.

• •Expansion of biologics, biosimilars, and cell and gene therapies is raising the share of shipments that require active temperature control.
• •ANVISA in Brazil and ANMAT in Argentina are tightening GDP-aligned expectations, pushing manufacturers to invest in qualified logistics partners.
• •Growing clinical trial activity in Latin America is adding demand for time- and temperature-sensitive Investigational Medicinal Product logistics.

The market can be segmented by service type (transport, warehousing, packaging, monitoring), by temperature range (2-8°C, -20°C, ultra-cold), and by product category (vaccines, biologics, clinical trial materials, APIs). Brazil is the deepest market due to its manufacturing footprint; Argentina and Colombia are emerging hubs, while the Andean and Southern Cone regions remain more dependent on imported cold chain services.

• •Transport (air and refrigerated road) represents the largest service line, followed by temperature-controlled warehousing near major airports and seaports.
• •Brazil (São Paulo, Rio de Janeiro), Argentina (Buenos Aires), and Colombia (Bogotá, Medellín) are the primary logistics nodes for pharma cold chain flows.
• •Smaller markets such as Chile, Peru, and Uruguay are growing fastest in percentage terms but from a low base.

What are the recent trends and outlook?

Over the medium term, the market is expected to keep growing at roughly 9-10% annually, supported by biologics expansion, more stringent regulation, and digitalization of monitoring. IoT-enabled sensors, AI-driven route optimization, and cloud-based temperature data platforms are moving from premium offerings to standard expectations. Resilience is also becoming a procurement criterion after pandemic-era disruptions.

• •Adoption of IoT temperature sensors and cloud-based data loggers is accelerating, with several large manufacturers requiring real-time visibility as standard.
• •Investment is rising in cold storage capacity near São Paulo (Guarulhos), Campinas, and Buenos Aires, including new GDP-certified facilities.
• •Sustainability considerations, including reusable passive containers and lower-emission refrigerated transport, are emerging as differentiators in tender processes.